Correction: Myeloablative conditioning for allo-HSCT in pediatric ALL: FTBI or chemotherapy?-A multicenter EBMT-PDWP study.

MLA

Willasch, Andre Manfred, et al. “Correction: Myeloablative Conditioning for Allo-HSCT in Pediatric ALL: FTBI or Chemotherapy?-A Multicenter EBMT-PDWP Study.” Bone Marrow Transplantation, vol. 56, no. 10, Oct. 2021, p. 2615. EBSCOhost, https://doi.org/10.1038/s41409-021-01424-5.

APA

Willasch, A. M., Peters, C., Sedláček, P., Dalle, J.-H., Kitra-Roussou, V., Yesilipek, A., Wachowiak, J., Lankester, A., Prete, A., Hamidieh, A. A., Ifversen, M., Buechner, J., Kriván, G., Hamladji, R.-M., Diaz-de-Heredia, C., Skorobogatova, E., Michel, G., Locatelli, F., Bertaina, A., … Bader, P. (2021). Correction: Myeloablative conditioning for allo-HSCT in pediatric ALL: FTBI or chemotherapy?-A multicenter EBMT-PDWP study. Bone Marrow Transplantation, 56(10), 2615. https://doi.org/10.1038/s41409-021-01424-5

Chicago

Willasch, Andre Manfred, Christina Peters, Petr Sedláček, Jean-Hugues Dalle, Vassiliki Kitra-Roussou, Akif Yesilipek, Jacek Wachowiak, et al. 2021. “Correction: Myeloablative Conditioning for Allo-HSCT in Pediatric ALL: FTBI or Chemotherapy?-A Multicenter EBMT-PDWP Study.” Bone Marrow Transplantation 56 (10): 2615. doi:10.1038/s41409-021-01424-5.